Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Retained Earnings (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Retained Earnings for 4 consecutive years, with $65000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.01% to $65000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65000.0 through Dec 2025, up 100.01% year-over-year, with the annual reading at $65000.0 for FY2025, 100.01% up from the prior year.
  • Retained Earnings for Q4 2025 was $65000.0 at Day One Biopharmaceuticals, up from -$640.1 million in the prior quarter.
  • The five-year high for Retained Earnings was $67000.0 in Q1 2023, with the low at -$640.1 million in Q3 2025.
  • Average Retained Earnings over 4 years is -$156.8 million, with a median of -$61500.0 recorded in 2022.
  • The sharpest move saw Retained Earnings surged 112.68% in 2023, then crashed 10668650.0% in 2025.
  • Over 4 years, Retained Earnings stood at -$71000.0 in 2022, then skyrocketed by 112.68% to $9000.0 in 2023, then crashed by 6156555.56% to -$554.1 million in 2024, then surged by 100.01% to $65000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $65000.0, -$640.1 million, and -$92000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.